 Catherine Jankowski
Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 28 | 2023 | 1643 | 4.200 |
Why?
| | HIV Infections | 29 | 2023 | 2469 | 3.070 |
Why?
| | Body Composition | 13 | 2021 | 592 | 1.680 |
Why?
| | Neoplasms | 7 | 2023 | 2105 | 1.400 |
Why?
| | Frailty | 5 | 2023 | 114 | 1.380 |
Why?
| | Bone Density | 8 | 2021 | 432 | 1.290 |
Why?
| | Dehydroepiandrosterone | 3 | 2018 | 49 | 1.270 |
Why?
| | Aging | 11 | 2023 | 1620 | 1.180 |
Why?
| | Quality of Life | 10 | 2023 | 2356 | 1.160 |
Why?
| | Caregivers | 3 | 2023 | 714 | 1.060 |
Why?
| | Muscle, Skeletal | 7 | 2023 | 1472 | 0.980 |
Why?
| | Exercise Therapy | 6 | 2021 | 351 | 0.870 |
Why?
| | Collagen Type I | 3 | 2021 | 108 | 0.840 |
Why?
| | Alkaline Phosphatase | 2 | 2021 | 143 | 0.810 |
Why?
| | Ibuprofen | 2 | 2021 | 74 | 0.810 |
Why?
| | Art Therapy | 1 | 2022 | 15 | 0.800 |
Why?
| | Muscle Strength | 2 | 2018 | 270 | 0.770 |
Why?
| | Aged | 33 | 2023 | 19078 | 0.770 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 82 | 0.720 |
Why?
| | Interleukin-6 | 2 | 2021 | 675 | 0.710 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 93 | 0.710 |
Why?
| | HIV Long-Term Survivors | 1 | 2020 | 3 | 0.700 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 299 | 0.690 |
Why?
| | Interleukin-10 | 1 | 2021 | 296 | 0.650 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 34 | 0.630 |
Why?
| | Attitude to Health | 2 | 2019 | 406 | 0.630 |
Why?
| | Anti-HIV Agents | 7 | 2020 | 666 | 0.610 |
Why?
| | Preventive Health Services | 1 | 2020 | 135 | 0.610 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 201 | 0.610 |
Why?
| | Peptides | 3 | 2021 | 848 | 0.610 |
Why?
| | Middle Aged | 36 | 2023 | 26747 | 0.580 |
Why?
| | Adiposity | 3 | 2013 | 457 | 0.580 |
Why?
| | Humans | 66 | 2023 | 114709 | 0.550 |
Why?
| | Perception | 1 | 2019 | 311 | 0.540 |
Why?
| | Adaptation, Physiological | 3 | 2021 | 483 | 0.530 |
Why?
| | Hormone Replacement Therapy | 3 | 2018 | 77 | 0.510 |
Why?
| | Telemedicine | 1 | 2023 | 663 | 0.490 |
Why?
| | Estrogens | 4 | 2013 | 312 | 0.490 |
Why?
| | Guidelines as Topic | 2 | 2019 | 244 | 0.480 |
Why?
| | Dehydroepiandrosterone Sulfate | 3 | 2013 | 45 | 0.480 |
Why?
| | Fatigue | 5 | 2022 | 295 | 0.480 |
Why?
| | Sex Factors | 2 | 2018 | 1717 | 0.450 |
Why?
| | Heart Failure | 2 | 2023 | 1952 | 0.450 |
Why?
| | Survivors | 2 | 2014 | 411 | 0.410 |
Why?
| | Inflammation | 3 | 2021 | 2481 | 0.400 |
Why?
| | Nausea | 2 | 2023 | 103 | 0.390 |
Why?
| | Female | 40 | 2023 | 59483 | 0.390 |
Why?
| | Bone and Bones | 2 | 2013 | 278 | 0.360 |
Why?
| | Physical Fitness | 4 | 2017 | 179 | 0.360 |
Why?
| | Resistance Training | 1 | 2012 | 113 | 0.360 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 1727 | 0.350 |
Why?
| | Male | 30 | 2023 | 55554 | 0.350 |
Why?
| | Acetaminophen | 1 | 2012 | 238 | 0.340 |
Why?
| | Health Status | 2 | 2020 | 723 | 0.330 |
Why?
| | Postmenopause | 5 | 2019 | 303 | 0.330 |
Why?
| | HIV-1 | 5 | 2020 | 768 | 0.310 |
Why?
| | Sarcopenia | 2 | 2023 | 63 | 0.300 |
Why?
| | Cross-Sectional Studies | 11 | 2023 | 4406 | 0.300 |
Why?
| | Menopause | 2 | 2021 | 271 | 0.290 |
Why?
| | Accelerometry | 2 | 2019 | 73 | 0.290 |
Why?
| | Pain | 2 | 2023 | 710 | 0.270 |
Why?
| | Glucose | 1 | 2011 | 897 | 0.270 |
Why?
| | Biomarkers | 6 | 2021 | 3414 | 0.270 |
Why?
| | Weight Loss | 4 | 2020 | 642 | 0.260 |
Why?
| | Cancer Survivors | 2 | 2021 | 206 | 0.260 |
Why?
| | Motor Activity | 3 | 2014 | 640 | 0.260 |
Why?
| | Qualitative Research | 4 | 2023 | 935 | 0.250 |
Why?
| | Social Stigma | 2 | 2023 | 87 | 0.240 |
Why?
| | Radioisotope Dilution Technique | 1 | 2004 | 13 | 0.240 |
Why?
| | Body Water | 1 | 2004 | 19 | 0.240 |
Why?
| | Urine | 1 | 2004 | 55 | 0.230 |
Why?
| | Serum | 1 | 2004 | 57 | 0.230 |
Why?
| | Absorptiometry, Photon | 4 | 2021 | 224 | 0.230 |
Why?
| | Deuterium | 1 | 2004 | 79 | 0.230 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2004 | 23 | 0.230 |
Why?
| | Parents | 2 | 2022 | 1190 | 0.230 |
Why?
| | Lumbar Vertebrae | 3 | 2018 | 209 | 0.220 |
Why?
| | Saliva | 1 | 2004 | 189 | 0.210 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6346 | 0.210 |
Why?
| | Femur | 2 | 2018 | 191 | 0.210 |
Why?
| | Malnutrition | 1 | 2023 | 63 | 0.200 |
Why?
| | Proxy | 1 | 2022 | 23 | 0.200 |
Why?
| | High-Intensity Interval Training | 1 | 2022 | 18 | 0.200 |
Why?
| | Adolescent | 6 | 2023 | 17806 | 0.200 |
Why?
| | Prospective Studies | 3 | 2023 | 6215 | 0.200 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 9 | 0.190 |
Why?
| | Symptom Assessment | 1 | 2023 | 118 | 0.190 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 42 | 0.190 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 46 | 0.190 |
Why?
| | Attitude | 1 | 2023 | 229 | 0.190 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 33 | 0.190 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 72 | 0.180 |
Why?
| | Child, Preschool | 4 | 2023 | 9077 | 0.180 |
Why?
| | Viral Load | 2 | 2020 | 405 | 0.170 |
Why?
| | Raloxifene Hydrochloride | 2 | 2013 | 13 | 0.170 |
Why?
| | Advance Directives | 1 | 2021 | 69 | 0.170 |
Why?
| | Interviews as Topic | 2 | 2020 | 582 | 0.170 |
Why?
| | Surveys and Questionnaires | 6 | 2023 | 4621 | 0.170 |
Why?
| | Cardiorespiratory Fitness | 1 | 2020 | 35 | 0.170 |
Why?
| | Protective Factors | 1 | 2020 | 87 | 0.170 |
Why?
| | Life Expectancy | 1 | 2020 | 51 | 0.170 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 305 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 521 | 0.170 |
Why?
| | Perimenopause | 1 | 2020 | 61 | 0.170 |
Why?
| | Blood Glucose | 4 | 2013 | 1821 | 0.170 |
Why?
| | DNA Methylation | 1 | 2023 | 496 | 0.170 |
Why?
| | Frail Elderly | 4 | 2023 | 105 | 0.160 |
Why?
| | Cell Phone | 1 | 2020 | 76 | 0.160 |
Why?
| | Placebos | 2 | 2011 | 198 | 0.160 |
Why?
| | Disabled Persons | 2 | 2018 | 132 | 0.160 |
Why?
| | Insulin | 5 | 2013 | 2079 | 0.160 |
Why?
| | Mexican Americans | 1 | 1999 | 102 | 0.150 |
Why?
| | Housing | 1 | 2019 | 114 | 0.150 |
Why?
| | Chronic Disease | 2 | 2021 | 1590 | 0.150 |
Why?
| | Advance Care Planning | 1 | 2021 | 197 | 0.150 |
Why?
| | Obesity | 3 | 2016 | 2513 | 0.140 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 232 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1214 | 0.140 |
Why?
| | Muscle Proteins | 1 | 2019 | 210 | 0.140 |
Why?
| | Self Care | 1 | 2020 | 350 | 0.140 |
Why?
| | Risk Factors | 7 | 2020 | 8625 | 0.140 |
Why?
| | Women's Health | 1 | 2019 | 271 | 0.140 |
Why?
| | Anxiety | 1 | 2023 | 840 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2018 | 125 | 0.130 |
Why?
| | Physical Therapists | 1 | 2017 | 39 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1134 | 0.130 |
Why?
| | Estradiol | 1 | 2019 | 455 | 0.130 |
Why?
| | Adaptation, Psychological | 2 | 2020 | 547 | 0.130 |
Why?
| | Adult | 13 | 2022 | 30542 | 0.130 |
Why?
| | Motivation | 4 | 2022 | 494 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 501 | 0.120 |
Why?
| | Stress, Psychological | 2 | 2020 | 944 | 0.120 |
Why?
| | Sleep | 1 | 2020 | 632 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 248 | 0.120 |
Why?
| | Decision Making | 1 | 2021 | 781 | 0.120 |
Why?
| | Child | 3 | 2023 | 18348 | 0.120 |
Why?
| | Activities of Daily Living | 1 | 2017 | 350 | 0.110 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 26 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 264 | 0.110 |
Why?
| | Microbiota | 1 | 2021 | 648 | 0.110 |
Why?
| | Developmental Disabilities | 1 | 2016 | 239 | 0.110 |
Why?
| | Risk Assessment | 2 | 2020 | 2973 | 0.110 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 207 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2008 | 1662 | 0.110 |
Why?
| | Depression | 2 | 2019 | 1133 | 0.110 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 116 | 0.100 |
Why?
| | Thigh | 2 | 2010 | 53 | 0.100 |
Why?
| | Public Health | 1 | 2017 | 434 | 0.100 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2012 | 22 | 0.100 |
Why?
| | Prognosis | 1 | 2020 | 3334 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 106 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2015 | 224 | 0.100 |
Why?
| | Lipids | 2 | 2013 | 582 | 0.100 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2011 | 36 | 0.090 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 218 | 0.090 |
Why?
| | Cholesterol, HDL | 1 | 2011 | 184 | 0.090 |
Why?
| | Osteogenesis | 1 | 2012 | 183 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2013 | 286 | 0.090 |
Why?
| | Hip | 2 | 2011 | 46 | 0.090 |
Why?
| | Accidental Falls | 1 | 2012 | 150 | 0.090 |
Why?
| | Osteoporosis | 1 | 2013 | 226 | 0.090 |
Why?
| | Subcutaneous Fat | 1 | 2010 | 70 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2011 | 307 | 0.090 |
Why?
| | Cholesterol | 1 | 2011 | 368 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 77 | 0.080 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 216 | 0.080 |
Why?
| | Triglycerides | 1 | 2011 | 470 | 0.080 |
Why?
| | United States | 3 | 2023 | 12175 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2013 | 476 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2013 | 3004 | 0.080 |
Why?
| | Geriatric Assessment | 2 | 2023 | 176 | 0.080 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2008 | 48 | 0.080 |
Why?
| | Dyslipidemias | 1 | 2010 | 154 | 0.080 |
Why?
| | Linear Models | 2 | 2008 | 770 | 0.080 |
Why?
| | Weight Gain | 1 | 2011 | 451 | 0.080 |
Why?
| | Area Under Curve | 2 | 2010 | 275 | 0.080 |
Why?
| | Body Mass Index | 3 | 2013 | 1958 | 0.080 |
Why?
| | Diet | 2 | 2006 | 1080 | 0.070 |
Why?
| | Vascular Stiffness | 1 | 2012 | 407 | 0.070 |
Why?
| | Focus Groups | 2 | 2019 | 385 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1316 | 0.070 |
Why?
| | Calcium, Dietary | 1 | 2006 | 55 | 0.070 |
Why?
| | Cognition | 1 | 2013 | 983 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 1999 | 2096 | 0.070 |
Why?
| | Regression Analysis | 1 | 2008 | 946 | 0.060 |
Why?
| | Testosterone | 1 | 2008 | 343 | 0.060 |
Why?
| | Florida | 1 | 2023 | 73 | 0.060 |
Why?
| | Social Support | 2 | 2018 | 527 | 0.060 |
Why?
| | Rest | 1 | 2004 | 103 | 0.050 |
Why?
| | C-Peptide | 1 | 2004 | 138 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1795 | 0.050 |
Why?
| | Vitamin D | 1 | 2006 | 341 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2004 | 343 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 257 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2010 | 1072 | 0.050 |
Why?
| | Habits | 1 | 2022 | 36 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2006 | 635 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1218 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2005 | 539 | 0.050 |
Why?
| | Actigraphy | 1 | 2020 | 74 | 0.040 |
Why?
| | Death | 1 | 2021 | 107 | 0.040 |
Why?
| | Premenopause | 1 | 2020 | 107 | 0.040 |
Why?
| | Energy Metabolism | 2 | 2013 | 729 | 0.040 |
Why?
| | Family | 1 | 2023 | 590 | 0.040 |
Why?
| | Postprandial Period | 1 | 1999 | 87 | 0.040 |
Why?
| | Counseling | 1 | 2021 | 342 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 737 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 121 | 0.040 |
Why?
| | Affect | 1 | 2020 | 245 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6122 | 0.030 |
Why?
| | Health Services for the Aged | 1 | 2017 | 70 | 0.030 |
Why?
| | Liver | 1 | 2004 | 1631 | 0.030 |
Why?
| | Heart Rate | 1 | 2020 | 704 | 0.030 |
Why?
| | Disabled Children | 1 | 2016 | 69 | 0.030 |
Why?
| | Smartphone | 1 | 2016 | 70 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 19 | 0.030 |
Why?
| | Professional Role | 1 | 2017 | 150 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1319 | 0.030 |
Why?
| | Tracheostomy | 1 | 2016 | 100 | 0.030 |
Why?
| | Self Efficacy | 1 | 2018 | 355 | 0.030 |
Why?
| | Aging, Premature | 1 | 2013 | 11 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 38 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 35 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 46 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2016 | 526 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3031 | 0.030 |
Why?
| | Amino Acids, Essential | 1 | 2012 | 12 | 0.030 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2012 | 31 | 0.030 |
Why?
| | Dietetics | 1 | 2012 | 22 | 0.030 |
Why?
| | Nutritional Support | 1 | 2012 | 27 | 0.030 |
Why?
| | Ovariectomy | 1 | 2012 | 116 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 320 | 0.020 |
Why?
| | United Kingdom | 1 | 2012 | 226 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 256 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 123 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 180 | 0.020 |
Why?
| | Bone Remodeling | 1 | 2011 | 65 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 4899 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 429 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 157 | 0.020 |
Why?
| | Weight Reduction Programs | 1 | 2011 | 94 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2321 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 559 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2012 | 588 | 0.020 |
Why?
| | Contraceptive Agents | 1 | 2010 | 54 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2381 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 951 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1044 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 629 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 913 | 0.020 |
Why?
| | Executive Function | 1 | 2013 | 376 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2012 | 460 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 718 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 689 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 965 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4085 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 2312 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 525 | 0.020 |
Why?
| | Buttocks | 1 | 2005 | 10 | 0.020 |
Why?
| | Abdomen | 1 | 2005 | 100 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 4420 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12511 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2012 | 5034 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2268 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9089 | 0.010 |
Why?
| | Infant | 1 | 2012 | 7932 | 0.010 |
Why?
| | Young Adult | 1 | 2010 | 10461 | 0.010 |
Why?
| | Eating | 1 | 1995 | 345 | 0.010 |
Why?
|
|
Jankowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|